A recent study confirms that the 100-year-old BCG vaccine does not protect against COVID-19, challenging early assumptions ...
Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...
ImmunityBio, Inc. , a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation's largest independent providers of urology and related specialty services, is one of the ...
A Tuberculosis (TB) outbreak in Kansas City, Kansas, has people on edge, with not much public knowledge about the disease or ...
ET Now on MSN13h
Aurobindo's CuraTeq Biologics Aims Doubling Down on Biosimilar Launches - 2031 Plans REVEALED | ET NOW On The Go Hyderabad EditionAurobindo, that last year signed a deal with U.S. drugmaker MSD to manufacture one of their biologics products at its ...
We recently compiled a list of the 12 Stocks Under $10 With High Upside Potential. In this article, we are going to take a ...
Nadofaragene firadenovec intravesical gene therapy continues to show promise in treating BCG-unresponsive NMIBC bladder cancer.
STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback